19 September 2019 
EMA/CHMP/503493/2019   
Committee  for Medicinal  Products for Human  Use (CHMP) 
Summary of opinion1  (post authorisation) 
Lucentis 
ranibizumab 
On 19 September 2019, the Committee for Medicinal  Products for Human Use (CHMP) adopted a positive 
opinion  recommending a change to the terms of the marketing  authorisation  for the medicinal  product 
Lucentis.  The marketing authorisation  holder for this  medicinal  product is  Novartis Europharm  Limited. 
The CHMP adopted an extension to the existing  indication  to add the treatment of proliferative  diabetic 
retinopathy  (PDR). 
For information,  the full  indication  for Lucentis  will  be as follows: 2 
“Lucentis  is indicated  in adults  for: 
• 
• 
• 
The treatment of neovascular (wet) age-related  macular  degeneration  (AMD) 
The treatment of visual  impairment  due to choroidal neovascularisation  (CNV) 
The treatment of visual  impairment  due to diabetic  macular  oedema (DME) 
•  The treatment of proliferative  diabetic  retinopathy  (PDR) 
• 
• 
The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch 
RVO or central RVO) 
The treatment of visual  impairment  due to choroidal neovascularisation  (CNV)  
Lucentis  is indicated  in  preterm infants  for: 
• 
The treatment of retinopathy  of prematurity  (ROP) with zone I  (stage 1+, 2+, 3 or 3+), zone II 
(stage 3+) or AP-ROP (aggressive  posterior ROP) disease.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics  (SmPC), which  will  be published  in  the revised  European public  assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation  has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
A n agenc y of the E uropean U nion   
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                 
